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Due to the abundance of seminal discoveries establishing a strong causal relation
between changes in aldosterone signaling, the activity of the epithelial Na+ channel
(ENaC) and blood pressure, the role of ENaC in health and disease is understood
almost exclusively through the concept that this channel functions (in the distal nephron)
as a key end-effector controlling renal sodium excretion during feedback regulation of
blood pressure by the renin-angiotensin-aldosterone system (RAAS). Recent findings of
aldosterone-independent stimulation of ENaC by vasopressin challenge the completeness
of dogmatic understanding where ENaC serves solely as an end-effector of the RAAS
important for control of sodium balance. Rather the consequences of activating ENaC in
the distal nephron appear to depend on whether the channel is activated in the absence (by
aldosterone) or presence [by vasopressin (AVP)] of simultaneous activation of aquaporin
2 water channels. Thus, a unifying paradigm has ENaC at the junction of two signaling
systems that sometimes must compete: one controlling and responding to changes
in sodium balance, perceived as mean arterial pressure, and the other water balance,
perceived as plasma osmolality.
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In many instances, particularly during hyponatremia and hyper-
natremia, plasma sodium likely contributes to the control of
blood pressure. As is clear when considering the action of diuret-
ics that suppress tubular sodium reabsorption, plasma sodium,
and thus blood pressure, is influenced by renal sodium excretion.
Renal sodium excretion is fine-tuned in the aldosterone-sensitive
distal nephron (ASDN). The epithelial Na+ channel (ENaC) is
expressed in the apical plasma membrane of principal cells of the
ASDN (Garty and Palmer, 1997; Kellenberger and Schild, 2002).
Here, ENaC serves as the primary cell entry pathway for electro-
genic Na+ reabsorption from the urine back into interstitial fluid.
Consequently, the activity of ENaC is limiting for trans-cellular
sodium reabsorption across the ASDN.
Normal ENaC function is required for proper sodium balance
and thus, normal blood pressure. Gain-of-function mutations
in ENaC cause inappropriate renal sodium retention and con-
sequent increases in mean arterial pressure (Lifton et al., 2001;
Rossier et al., 2002). Inhibition of ENaC corrects the renal and
blood pressure phenotypes resulting from such mutations. Loss-
of-function mutations in ENaC, in contrast, cause renal sodium
wasting and corresponding decreases in blood pressure (Rossier
et al., 2002; Geller, 2005).
As a key end-effector modulating blood pressure, the activ-
ity of ENaC in the ASDN, as depicted in (the right of) Figure 1
is under negative-feedback regulation by the renin-angiotensin-
aldosterone system (RAAS). The mineralocorticoid, aldosterone,
is the final hormone in this cascade. This anti-natriuretic fac-
tor is essential for proper Na+ balance (Horisberger and Diezi,
1983). Decreases in blood pressure evoke via renin-AngII signal-
ing secretion of aldosterone from the adrenal gland. Aldosterone
through the mineralocorticoid receptor (MR) stimulates ENaC
in the ASDN to minimize renal sodium excretion in protec-
tion of plasma sodium (Rossier et al., 2002; Geller, 2005).
Pathological increases in aldosterone elevate blood pressure by
promoting inappropriate renal sodium retention (White, 1994;
Gomez-Sanchez, 1998). Inhibition of ENaC ameliorates this. In
contrast, pathological decreases in aldosterone result in sodium
wasting arising from inappropriate increases in renal sodium
excretion (White, 1994; Geller, 2005). MR agonism and antago-
nism increase and decrease ENaC activity, respectively (Kemendy
et al., 1992; Pácha et al., 1993; Palmer et al., 1994). Simply put,
there is strong support for a tight positive relation between the
levels and actions of aldosterone and ENaC activity, renal sodium
reabsorption and blood pressure. In this sense, activation of ENaC
is anti-natriuretic protecting plasma sodium and blood pressure.
Because of the abundance of seminal discoveries establish-
ing this strong causal relation between changes in aldosterone,
ENaC activity and blood pressure, the role of ENaC in health
and disease is understood almost exclusively through the con-
cept of feedback regulation by the RAAS (Garty and Palmer,
1997; Lifton et al., 2001; Rossier et al., 2002; Geller, 2005).
Emerging evidence, though, argues that this dogma is inadequate
too narrowly defining the role of ENaC in sodium and water
balance. For instance, ENaC activity is high, in some instances,
in the absence of significant changes in aldosterone (Palmer
et al., 1994; Mironova et al., 2012). This form of regulation is
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FIGURE 1 | Regulation of ENaC by aldosterone and vasopressin.
Vasopressin release is stimulated primarily by increases in plasma
osmolality but also by decreases in mean arterial pressure and is also under
feedback control by the hypothalamic-pituitary-adrenal (HPA) axis as
mediated by glucocorticoids. Positive and negative relations are indicated
by blue and red, respectively. Weaker regulation indicated with narrower
arrows.
termed aldosterone-independent in the current review. Several
hormones in addition to aldosterone modulate the activity of
ENaC. Vasopressin (AVP) decreases renal sodium excretion by
increasing the activity of ENaC and sodium reabsorption in
the ASDN in parallel with aldosterone (Bankir, 2001; Perucca
et al., 2008; Stockand, 2010; Blanchard et al., 2011). Indeed, both
AVP and aldosterone are required to achieve maximal urinary
concentration: minimization of free water excretion.
The antidiuretic hormone, AVP, increases free water reab-
sorption by stimulating aquaporin 2 water channels in the dis-
tal nephron (Bankir, 2001; Fenton and Knepper, 2007). The
axial corticomedullary hyperosmotic gradient as established by
the loop of Henle provides the draw for this AQP2-mediated
water reabsorption. In addition to being anti-aquaretic, AVP is
anti-natriuretic (Helman et al., 1971; Frindt and Burg, 1972;
Andersen et al., 1990; Bankir et al., 2005). As extrapolated from
rich but indirect evidence, ENaC, as shown in (the left of)
Figure 1, appears to be a target for AVP in this regard. AVP
stimulates sodium reabsorption in isolated perfused ASDN in
an amiloride-sensitive manner, and amiloride inhibits the anti-
natriuretic actions of AVP in man (Helman et al., 1971; Frindt
and Burg, 1972; Reif et al., 1984; Tomita et al., 1986; Schlatter
and Schafer, 1987; Hawk et al., 1996). Amiloride is a blocker
of ENaC. Moreover, V2 receptor antagonism promotes sodium
excretion in addition to water excretion (Andersen et al., 1990;
Bankir, 2001; Bankir et al., 2005; Perucca et al., 2008). The V2
receptor mediates AVP actions in the ASDN (see Stockand, 2010
for a recent review of AVP signaling and actions on ENaC in the
ASDN). AVP also increases the trans-epithelial voltage difference
across isolated ASDN consistent with it activating electrogenic
transport processes (Helman et al., 1971; Frindt and Burg, 1972;
Reif et al., 1984; Schlatter and Schafer, 1987; Hawk et al., 1996).
Cell entry of sodium across the apical membrane via ENaC, as
discussed above, is the limiting step in electrogenic sodium reab-
sorption in the ASDN. Moreover, AVP increases the activity of
ENaC in cultured immortalized renal cells (Marunaka and Eaton,
1991). Recently, we demonstrated that AVP increases the activity
of ENaC in freshly isolated, split-openmurine ASDN (Bugaj et al.,
2009).
As discussed above, regulation of plasma sodium and thus, vol-
ume is considered to be under the purview of the RAAS with
ENaC playing a critical role in this process; and plasma osmo-
lality under the control of feedback regulation by AVP with AQP2
being the critical end-effector in this process. However, the com-
pelling support for AVP-activation of ENaC suggests that these
paradigms need to be broadened to incorporate the concept that
activation of ENaC in the presence of activated AQP2 contributes
to the draw for water reabsorption out of the ASDN. This would
be consistent with the function of ENaC (in the presence of
activated AQP2) being shifted by AVP from protecting plasma
sodium to facilitating water reabsorption. This exciting idea raises
several questions centered on the hypothesis that the function of
ENaC in the ASDN (with respect to systemic sodium and water
balance) dependents on whether the channel is activated in the
absence or presence of simultaneous activation of AQP2 water
channels where AVP activates both ENaC and AQP2.
Upon initial consideration, the idea that AVP-activated ENaC
facilitates free water reabsorption seems counter-intuitive to the
established role for this channel in protecting plasma sodium.
However, the essential question here is whether ENaC activated
in the ASDN in the presence of AQP2 contributes more to the
draw for free water reabsorption or plasma [Na+]: a question that
largely remains to be answered. Insight, though, can be gleamed
from several recent findings as discussed below.
Addressing whether ENaC activated in the presence of active
AQP2 by AVP influences the draw for free water more than
plasma [Na+] is significant for it will define the paradigm (refer
to Table 1) by which we understand the role of ENaC in hypona-
tremic and hypernatremic states of low aldosterone but high AVP.
Elaboration of this question, moreover, is significant because it
also will define the limitations of having two distinct feedback
systems, one responsive to and controlling plasma [Na+]/volume
and the other plasma osmolality/water content, competing using
a common final effector, ENaC (refer to Table 1).
ALDOSTERONE SIGNALING THROUGHMR IS SUFFICIENT
BUT IS IT NECESSARY FOR ENaC ACTIVITY?
All studies investigating the actions of aldosterone on (amiloride-
sensitive) renal sodium excretion, transport and the activity of
ENaC in the ASDN are in agreement that increases in aldos-
terone are sufficient to increase ENaC activity (Pácha et al.,
1993; Palmer et al., 1994). Decreased amiloride-sensitive sodium
excretion resulting from gain-of-function mutations in MR and
increases in aldosterone signaling also are in agreement on this
point (White, 1994; Gomez-Sanchez, 1998; Geller, 2005).
The strong inverse relation between sodium intake and aldos-
terone levels and ENaC activity are consistent with aldosterone
being necessary for the activity of this channel. In agreement are
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Table 1 | The consequences of active ENaC in states of high AVP and low aldosterone.
State AVP Aldo ENaC activity Volume PNa Potential role of ENaC decreasing excretion ofa
Sodium Free water
Adx ↑ ↓ Robust ↓ ↓ Compensatory to volume Causal to hyponatremia
SIADH ↑ ↓ ? – ↓ Compensatory to hyponatremia Causal to hyponatremia
aThe role of ENaC will depend on whether it has a relatively greater effect on decreasing renal sodium excretion vs. free water excretion.
findings thatMR antagonism decrease ENaC activity and increase
renal sodium excretion (Pácha et al., 1993; Palmer et al., 1994).
Moreover, recent results form genetically modified mice lacking
MR or aldosterone synthase (AS) also support this position. MR
null mice do not survive long after the first week of life without
sodium supplementation due to pathological renal sodium excre-
tion (Berger et al., 1998). Similarly, AS null mice have pronounced
renal sodium and water wasting (Lee et al., 2005; Makhanova
et al., 2006). Sodium restriction exacerbates renal salt and water
wasting in both AS and MR null mice as compared to control
animals, which have appropriate feedback regulation of ENaC by
RAAS. These observations are reminiscent of human infants car-
rying inactivatingMRmutations andAS deficiency, which require
sodium supplementation to survive (White, 1994, 2004; Geller,
2005).
However, this issue is more complex than the above find-
ings would seem to suggest. It was demonstrated recently that
the inverse relation between sodium intake and ENaC activity
is not solely dependent on aldosterone signaling (Toney et al.,
2012), and neonatal MR null mice retain residual but signifi-
cant ENaC activity, approximately 24% of normal, as extrapolated
from amiloride-sensitive fractional Na+ excretion and transport
across isolated, perfused collecting ducts (Berger et al., 1998).
Such results are not consistent with aldosterone being an absolute
requirement for ENaC activity in the ASDN. The strongest sup-
port for this, though, comes from recent findings that ENaC is
expressed and active in the absence of aldosterone in adrenalec-
tomized mice (Mironova et al., 2012). Thus, there are some
instances where ENaC is active in the absence of aldosterone sig-
naling. These exceptions then demonstrate that aldosterone is
not necessary for the activity of ENaC in the ASDN. This raises
the questions of what is maintaining ENaC activity high in the
absence of aldosterone in these circumstances and what are the
consequences of aldosterone-independent activation of ENaC.
ALDOSTERONE-INDEPENDENT ACTIVATION OF ENaC
BY AVP IN HYPONATREMIC STATES
The first clue to answering these questions comes from under-
standing that the hormonal state and thus phenotype of loss-
of-function of MR or AS does not completely overlap that of
adrenalectomy. With MR dysfunction, the RAAS is up-regulated
(Berger et al., 1998). With AS dysfunction, aldosterone is absent
but the levels of other adrenal steroids capable of mineralocor-
ticoid action, in particular corticosterone, are increased (White,
2004; Lee et al., 2005). With adrenalectomy, there is no aldos-
terone or other adrenal steroids and catecholamines and thus,
these animals receive no input from the adrenal gland to ENaC.
Moreover, akin to adrenal insufficiency, removal of the adrenal
glands causes marked increases in plasma AVP levels (Friedman
et al., 1962b; Ahmed et al., 1967; Ishikawa and Schrier, 2003).
This is not present with eitherMRor AS dysfunction (Makhanova
et al., 2006).
Usually, AVP release is primarily controlled by plasma osmo-
lality. Elevated AVP release in adrenal insufficient states (that lack
both glucocorticoids and mineralocorticoids) results form two
events. There is loss of negative-feedback regulation by glucocor-
ticoids of the hypothalamic-pituitary axis controlling AVP release
and there is strong non-osmotic stimulation of AVP release result-
ing from volume depletion due to sodium and water wasting by
the kidney (Ahmed et al., 1967; Ishikawa and Schrier, 2003).
The second clue comes from recognizing that adrenal insuf-
ficiency and central diabetes insipidus are counterpoints when
considering the equilibrium distribution of sodium and water:
the pattern of sodium and water distribution in either deficiency
depends in part on the activity of the remaining gland. As such,
the hyponatremia of adrenal insufficiency is absent when com-
bined with neurohypophyseal deficiency and in the Brattleboro
rat, which has central diabetes insipidus (Friedman et al., 1962a,b;
Foy and Schnieden, 1965; Ahmed et al., 1967). Thus, the hypona-
tremia of adrenal insufficiency is dependent on elevated AVP
release.
As discussed above, AVP is known to decrease renal Na+
excretion by increasing reabsorption in the ASDN by stimulat-
ing ENaC activity. Akin to its regulation of AQP2 water chan-
nels, AVP stimulates ENaC in principal cells via the V2 receptor
(Bugaj et al., 2009; Stockand, 2010). Inhibition of the V2 recep-
tor decreases ENaC activity in the ASDN of adrenaletomized
mice to levels that are identical to those observed in control ani-
mals (Mironova et al., 2012). This demonstrates that elevated
AVP is the driving force maintaining ENaC activity high in the
absence of aldosterone in adrenalectomized mice. Could this
aldosterone-independent AVP-stimulation of ENaC (in the pres-
ence of activated AQP2) be contributing to the draw of water out
of the collecting duct and thus, be contributing to the hypona-
tremia common to adrenal insufficiency? As depicted in Table 1
only additional research will clarify this issue.
To appreciate the potential consequences of aldosterone-
independent activation of ENaC by AVP, it must be recognized
that with adrenalectomy ENaC is no longer regulated in a normal
manner by feedback signaling in response to changes in sodium
balance. This is a result of stimulation by elevated AVP release
combined with disruption of regulation by the RAAS. Rather in
adrenal insufficient states, ENaC is regulated primarily by AVP: a
hormone that normal controls plasma osmolality.
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Adrenalectomy, similar to other adrenal insufficient states,
though, causes pronounced renal sodium and volume wasting;
likely through loss of a non-ENaC, aldosterone-dependent but
AVP-insensitive mechanism (Mironova et al., 2012). This mud-
dies the waters with respect to whether AVP-dependent stimula-
tion of ENaC in adrenal insufficiency is a compensatory response
to decreases in volume or a result independent of actions on vas-
cular volume. It is noteworthy that AS and MR null mice also
have significant renal salt and water and thus, volume loss but
the activity of ENaC under these conditions, which are not noted
for significant increases in [AVP], is markedly less than that in
adrenalectomized mice, which do have elevated [AVP]. Regardless
of whether increases in ENaC activity are compensatory or not,
a consequence of adrenal insufficiency is that AVP-stimulated
ENaC, in the absence of input from RAAS, becomes a slave to
water reabsorption rather than a key mediator of sodium balance
possibly exacerbating the hyponatremia of this state. As outlined
in Table 1, a definitive test of the role of AVP-activated ENaC dur-
ing adrenal insufficiency will be to determine whether blockade
of this channel betters or worsens the hyponatremia of this state.
As yet these experiments have not been performed.
Unlike adrenal insufficiency, hyponatremia in the syndrome of
inappropriate ADH (AVP) secretion (SIADH) is not associated
with hypovolemia. No results are available currently regarding
ENaC activity in this condition and thus, it is unclear if increases
in AVP in this setting also stimulate ENaC. Prolonged agonism
of the V2 receptor in a rat model of SIADH, though, increased
ENaC abundance even in the absence of input from the adrenal
gland (Ecelbarger et al., 2001; Tiwari et al., 2006). Unfortunately,
no information exists currently regarding whether inhibition of
ENaC betters or worsens hyponatremia in SIADH. Such stud-
ies are key for they will elaborate the effects of AVP-dependent
stimulation of ENaC in hyponatremic states with and without
confounding hypovolemia.
CONCLUDING REMARKS
While several key questions remain about the physiological and
pathological consequences of AVP-stimulation of ENaC, it is clear
that AVP can increase the activity of this channel. This posi-
tions ENaC to be an end-effector of both aldosterone, as the final
signal in the RAAS and AVP. Signaling through RAAS, in part
because it activates ENaC, influences plasma sodium and thus,
blood pressure; and signaling by AVP influences free water reab-
sorption, in part, because it activates AQP2. As argued above,
AVP-stimulated ENaC likely facilitates water reabsorption. This
contributes to protection of vascular volume as likely is the case
in adrenal insufficiency, but does it do so at the expense of facil-
itating hyponatremia? Such a question highlights the potential
limitations imposed by the mechanics of water movement only
through osmosis in biological systems and by the evolution of the
mammalian renal tubule where ENaC sits at the intersection of
two homeostatic control systems one responding to and influenc-
ing plasma sodium, and the other plasma osmolality that must by
their nature sometimes be in competition.
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